NovelMed Therapeutics Inc

Business news, market intelligence, and global industry analysis.

The Latest

Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?

realme Buds T310 in Agile White: top true wireless earbuds under ₹2,000

realme Buds T310 review: Are these the best budget ANC earbuds under ₹2,000?

Why support-platform strategy may become a differentiator in schizophrenia treatment markets

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?

NovelMed Therapeutics advances Ruxoprubart with Phase II PNH results and a subcutaneous trial. Discover how it could reshape the complement inhibitor market.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 12, 2026